The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
I agree, no more placings to be done without SH say so. We can't back irrational decisions when the SP is at 11p it's crazy.
Do the bod not realise they could do a placing as much as they want at 40p with a reduction to 25-30p and nobody would bat an eyelid.
A firm NO from me!
The one and only LEGEND! Amongst us!!!
Evening.
Good grief, I’ve read some tosh on here today.
Nick Slater with inside information; absolute nonsense. VAL in my opinion are, if anything, overly conservative, so whoever thinks that is well and truly shooting at a very wrong target. This is precisely the reason that I felt the role of “shareholder rep” was somewhat fruitless.
Nick can defend himself, but I can tell you that, as a man whom is vocal in his opinion, sometimes he simply didn’t rub so well with the BOD and, as a result, felt that he wanted to reduce his holding. It’s as simple as that. A shame, as he made many germane suggestions, and continues to do so. Some folk with differing approaches don’t mix so well, and we are where we are, but I can also tell you that although he wants to make money, he also wants, to the same degree, every other genuine investor to make money at the same time, in addition to the BOD. He was a firm supporter of the bonus scheme and I’d wager, in fact, he’d have had it higher. Lots of experience in the markets, and always worth listening to in my opinion.
Aside from that, as Nick has taken a proverbial back-seat in his professional offerings, plus, as everyone in pharma loves “stretched” targets, here are mine for 2023:
I’d like to see one of the two remaining evaluation projects locked into an SPV (obviously two more would be most welcome!), with potentially two more entering evaluation. Out of five SPVs, I think that two could go all the way. Big pharma still has very deep pockets, and I’m seeing some fairly average compounds going through to meet numerical targets, currently. Some are even pushed through, even though there is no indication that they will afford greater efficacy than competitor compounds, which are often further on. KCTNBC is unique, and has, as far as I’m aware, no competition. It would truly be a first-in-class, so hopefully the conversations have commenced. Value accretion occurs over two years, but this could generate early interest, at least in my view. VAL have just published a superb piece on the website – this needs to be communicated via social media, far-and-wide.
I’d like to see a resolution regarding 201, before Spring, either way. Beyond this stage, it may materially impact the momentum built from the new compounds, and I don’t want that to happen. If 201 is signed over, I will doth my cap.
I’d like to see 301 with a new patent or indication, and perhaps bring a resolution to the Japanese partnership. Partnering 201 and 301 was a three-year target by the BOD themselves, as of 2021, so I feel aligned with them in this.
The lab is an astute idea, and should be being instigated as we speak. To be able to offer this as an in-house service will be a BIG draw to early potential partners, will streamline in-house compound development, and will generate revenue. By 2Q, I would hope that some potential customers will be lined up. I expect Cenkos, at this stage, to be able to attract an Institutional Investor on-board, who is interested in providing some capital for growth. If the BOD have demonstrated the model on a shoe-string budget, and Cenkos are unable to do this, then I would at that stage encourage the BOD to explore another main broker. I don’t think that we need a joint broker in a Company of this size.
BC201 should publish in the next six months, and I’d expect an update regarding 401, but as a “nice-to-have”. It remains to me a slight tragedy that no one has been willing to explore 401 in a further trial, as cancer-related cachexia is a massive unmet medical need.
The management team have my full support, and I’d also be fully behind any new BOD/NED buys; confident in the knowledge that all genuine holders want the BOD to do well, stay on, and deliver, which I expect this year. I want to see an end to VAL as a purely trading share, which it is currently if we are honest with ourselves.
If we hit levels at which the BOD can generate options, that would be fantastic. If they do well, retail holders are also doing very well.
The next two quarters have inflection written all over them, and it is time that lady luck gave the Company a thumbs up. There’s been a lot of hard work over the last twelve months, and so something good is due.
The BOD have some good tools to hand, so let’s see what they make.
Good luck to all genuine investors.
London South East
Our latest Investing Matters podcast episode featuring the London Stock Exchange's Director & Tech Sector Specialist, Neil Shah has just been released. Listen here.
Share PricesValirx Share PriceValirx Share Chat
Pin to quick picksValirx Share Chat (VAL)
VAL Share Price
VAL Share
Price
VAL Share News
VAL Share
News
VAL Share Chat
VAL Share
Chat
33
VAL Share Trades
VAL Share
Trades
15
VAL Live RNS
VAL
Live RNS
VAL Information Buy VAL SharesBuy VAL SharesAdd VAL to WatchlistAdd VAL to WatchlistAdd VAL to AlertAdd VAL to AlertAdd VAL to myTerminalAdd VAL to myTerminal
Share Price Information for Valirx (VAL)
London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
13.50
Bid:
13.00
Ask:
14.00
Change:
0.85 (6.72%)
Spread: 1.00 (7.69%)Open: 12.65High: 13.50Low: 12.65Prev. Close: 12.65
VAL Live PriceLast checked at 14:19:58
Share Discussion for Valirx
Regular
Premium
Filters
Thread View
Post Message
25
123
iceman888 Premium Member
Posts: 6,683
Price: 12.65
Strong Buy
RE: TargetsToday 08:56
Great post Adam!
Very refreshing and encouraging posts! Lots to look forward to. I think it will be the best year since the company started! I think VAL 301 and Val 401 will surprise us all !
Im with you as far as supporting the BOD and would love to see them buying few shares. I think its best to leave Suzy to do her work. We are due a quarterly update at the end of February 2023 and a Zoom call end of March.
SUZY, maybe its best to stop reading this BB. You dont need constant distraction. im sure when you read things here it does affect your state of mind. It takes your mind off work. I would just focus on my work and deliever results. Our frustration is due to lack of progress! So show some progress and im sure everyone will be very happy.
ReplyRecommend (5)Report Post
rhd1
Posts: 42
Price: 12.50
No Opinion
RE: Just copied and pasted a well presented positive post on ADVFNToday 07:58
Freddleboy,
Do you have a date for the opinion used in the cut and paste please?
ReplyRecommendReport Post
jjp1985
Posts: 624
Price: 12.50
No Opinion
RE: TargetsToday 07:58
If you have any concerns then feel free to contact the FCA, that is what they are there for, rather than spouting on here.
Our management team are unbelievably strict when it comes to releasing information and Suzy is overly cautious!!!
ReplyRecommend (8)Report Post
THEDARKKNIGHTS
Posts: 1,214
Price: 13.00
Strong Buy
RE: TargetsToday 07:51
Your posts are being removed because they are libellous I’m afraid Dark,you can get yourself in serious trouble. You can’t say that I’m afraid with no proof. I don’t think you are a bad guy but you are being a bit silly with this so I’m gently warning you.
ReplyRecommend (4)Report Post
jjp1985
Posts: 624
Price: 12.65
No Opinion
RE: TargetsToday 07:49
DarkHero - I'm no mate of y
Instead of going back and forth, il just leave Adams post right here, fantastic post :)
Evening.
Good grief, I’ve read some tosh on here today.
Nick Slater with inside information; absolute nonsense. VAL in my opinion are, if anything, overly conservative, so whoever thinks that is well and truly shooting at a very wrong target. This is precisely the reason that I felt the role of “shareholder rep” was somewhat fruitless.
Nick can defend himself, but I can tell you that, as a man whom is vocal in his opinion, sometimes he simply didn’t rub so well with the BOD and, as a result, felt that he wanted to reduce his holding. It’s as simple as that. A shame, as he made many germane suggestions, and continues to do so. Some folk with differing approaches don’t mix so well, and we are where we are, but I can also tell you that although he wants to make money, he also wants, to the same degree, every other genuine investor to make money at the same time, in addition to the BOD. He was a firm supporter of the bonus scheme and I’d wager, in fact, he’d have had it higher. Lots of experience in the markets, and always worth listening to in my opinion.
Aside from that, as Nick has taken a proverbial back-seat in his professional offerings, plus, as everyone in pharma loves “stretched” targets, here are mine for 2023:
I’d like to see one of the two remaining evaluation projects locked into an SPV (obviously two more would be most welcome!), with potentially two more entering evaluation. Out of five SPVs, I think that two could go all the way. Big pharma still has very deep pockets, and I’m seeing some fairly average compounds going through to meet numerical targets, currently. Some are even pushed through, even though there is no indication that they will afford greater efficacy than competitor compounds, which are often further on. KCTNBC is unique, and has, as far as I’m aware, no competition. It would truly be a first-in-class, so hopefully the conversations have commenced. Value accretion occurs over two years, but this could generate early interest, at least in my view. VAL have just published a superb piece on the website – this needs to be communicated via social media, far-and-wide.
I’d like to see a resolution regarding 201, before Spring, either way. Beyond this stage, it may materially impact the momentum built from the new compounds, and I don’t want that to happen. If 201 is signed over, I will doth my cap.
I’d like to see 301 with a new patent or indication, and perhaps bring a resolution to the Japanese partnership. Partnering 201 and 301 was a three-year target by the BOD themselves, as of 2021, so I feel aligned with them in this.
There is Georgie Porgie, thousands you pulled from my pockets, if i had my way your head would be on a spike but we dont live in the 1600, such a shame! but I'm glad i have made most of it back. And Suzy will bring a lot more valu to Valirx than you ever could.
DarkHero - you stated large SHs in a previous message I e therfore you don't hold much. Fool
Hahahaha hypocrisy, I was stating facts, you are just talking a load of rubbish about NS.
Now run along like a good lad, before you get your fingers burnt
Dark Hero - hahahaha now this is the vital part of why I can comment on Georgie Porgie because we had evidence of internal ongoing that wasn't in the best interests of SHs and the company, that's why they had to step down.
You're just chatting rubbish you fool
Dark Hero - ok so since we are addressing each other how we see fit, I will refer to you as Ahole as it is very fitting to what comes out of your mouth. Utter SH#T!!!
So you don't hold many shares but you still feel you can complain endlessly about others but people can't comment on you, what reality are you in haha fool
The other holders your speak of are old Valkrx employees that are bitter.
The way Satu rocks up to the AGM hahaha like she is owed something.
The only thing you two are owed is in a prison cell from all the money you defrauded out of SHs. Its embarrassing that you even post on here hahaha can't even enjoy retirement, you can't let go. Valirx will always haunt you until you die, because you just couldn't make it a success.
And neither can you state Georgie Porgie (Valtree) that fund raising is happening this month.
Adam has more class in his little finger than you have ever had within Pharma industry over 20-30yrs, you're an old bitter fool with no life. And has to put up with that old bag Satu next to you.
If you have any concerns then feel free to contact the FCA, that is what they are there for, rather than spouting on here.
Our management team are unbelievably strict when it comes to releasing information and Suzy is overly cautious!!!
DarkHero - I'm no mate of yours so don't address me as one.
IF, you hold 1 share or a million nobody cares as you are putting doubt and serious allegations against the management team of company that you state hold shares in. That is why each post is being removed because LSE have a duty to remove slanderous comments to protect you and the company.